FEB 12, 2009
Comprehensive Ophthalmology, Retina/Vitreous
Researchers treated five patients with a single intravitreal injection of 4.0 mg of VEGF Trap-Eye, and followed them for six weeks. No ocular toxicity was observed. At six weeks, four of the five patients showed improvement in foveal thickness (median 31 percent reduction from baseline) and improvement in BCVA (median improvement of three letters). Compared with Lucentis, VEGF Trap-Eye has a longer half-life after intraocular injection, a higher binding affinity to VEGF-A, and it binds to other members of the VEGF family, including placental growth.
Discuss this article
Tell us your thoughts on this article, and see your ideas posted online in our new ONE Opinion feature. Don't forget to include the article title in the subject line.